SM
Superluminal Medicines, Inc.
SEC filingBiotechnology · Boston, MA
Amount raised$65.5Msold at filing
Total offering$65.5M
Investors in the raise16count reported to the SEC
FiledSep 3, 2026first sale Aug 10, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
HARSHA PALADUGUDirector
DIAMANTIS XYLASDirector
DYLAN MORRISDirector
CONY D'CRUZExecutive Officer, Director, Promoter
NANDITA SHANGARIDirector
Executive officers, directors and promoters as listed on the Form D.